Annual SGA
$70.09 M
-$3.98 M-5.37%
December 31, 2023
Summary
- As of February 8, 2025, TBPH annual SGA is $70.09 million, with the most recent change of -$3.98 million (-5.37%) on December 31, 2023.
- During the last 3 years, TBPH annual SGA has fallen by -$38.44 million (-35.41%).
- TBPH annual SGA is now -35.41% below its all-time high of $108.53 million, reached on December 31, 2020.
Performance
TBPH SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly SGA
$16.88 M
-$181.00 K-1.06%
September 30, 2024
Summary
- As of February 8, 2025, TBPH quarterly SGA is $16.88 million, with the most recent change of -$181.00 thousand (-1.06%) on September 30, 2024.
- Over the past year, TBPH quarterly SGA has increased by +$733.00 thousand (+4.54%).
- TBPH quarterly SGA is now -48.93% below its all-time high of $33.05 million, reached on December 31, 2019.
Performance
TBPH Quarterly SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM SGA
-$3.72 B
-$49.40 M-1.35%
September 30, 2024
Summary
- As of February 8, 2025, TBPH TTM SGA is -$3.72 billion, with the most recent change of -$49.40 million (-1.35%) on September 30, 2024.
- Over the past year, TBPH TTM SGA has dropped by -$3.79 billion (-5310.86%).
- TBPH TTM SGA is now -21720.75% below its all-time high of -$17.04 million.
Performance
TBPH TTM SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Selling, General & Administrative Expenses Formula
SGA = Total Operating Expenses - Cost of Goods Sold - Research & Development
TBPH Selling, General & Administrative Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -5.4% | +4.5% | -5310.9% |
| 3 y3 years | -35.4% | -20.8% | -3551.3% |
| 5 y5 years | -27.8% | -43.6% | -3525.0% |
TBPH Selling, General & Administrative Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -34.9% | at low | -21.6% | +8.9% | -7.3% | +46.4% |
| 5 y | 5-year | -35.4% | at low | -48.9% | +8.9% | -7.3% | +46.4% |
| alltime | all time | -35.4% | +172.5% | -48.9% | +148.6% | <-9999.0% | +46.4% |
Theravance Biopharma Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $16.88 M(-1.1%) | $66.17 M(+1.1%) |
| Jun 2024 | - | $17.06 M(+1.9%) | $65.43 M(-3.3%) |
| Mar 2024 | - | $16.74 M(+8.1%) | $67.65 M(-3.5%) |
| Dec 2023 | $70.09 M(-5.4%) | $15.49 M(-4.0%) | $70.09 M(-1.7%) |
| Sep 2023 | - | $16.14 M(-16.3%) | $71.33 M(-0.2%) |
| Jun 2023 | - | $19.28 M(+0.5%) | $71.47 M(+4.5%) |
| Mar 2023 | - | $19.18 M(+14.6%) | $68.41 M(+2.0%) |
| Dec 2022 | $74.07 M(-31.2%) | $16.73 M(+2.8%) | $67.07 M(-6.7%) |
| Sep 2022 | - | $16.28 M(+0.3%) | $71.86 M(-6.5%) |
| Jun 2022 | - | $16.22 M(-9.1%) | $76.88 M(-11.2%) |
| Mar 2022 | - | $17.84 M(-17.1%) | $86.59 M(-12.8%) |
| Dec 2021 | $107.66 M(-0.8%) | $21.52 M(+1.0%) | $99.30 M(-7.8%) |
| Sep 2021 | - | $21.30 M(-17.9%) | $107.70 M(-5.4%) |
| Jun 2021 | - | $25.93 M(-15.1%) | $113.91 M(+1.0%) |
| Mar 2021 | - | $30.55 M(+2.1%) | $112.76 M(+3.9%) |
| Dec 2020 | $108.53 M(+2.3%) | $29.93 M(+8.8%) | $108.53 M(-2.8%) |
| Sep 2020 | - | $27.50 M(+11.0%) | $111.65 M(+1.7%) |
| Jun 2020 | - | $24.78 M(-5.9%) | $109.77 M(+2.4%) |
| Mar 2020 | - | $26.32 M(-20.3%) | $107.22 M(+1.1%) |
| Dec 2019 | $106.08 M(+9.3%) | $33.05 M(+29.0%) | $106.08 M(+7.7%) |
| Sep 2019 | - | $25.62 M(+15.3%) | $98.49 M(+3.9%) |
| Jun 2019 | - | $22.23 M(-11.7%) | $94.76 M(-2.9%) |
| Mar 2019 | - | $25.19 M(-1.1%) | $97.54 M(+0.5%) |
| Dec 2018 | $97.06 M | $25.46 M(+16.3%) | $97.06 M(-4.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | $21.89 M(-12.5%) | $101.12 M(+0.9%) |
| Jun 2018 | - | $25.01 M(+1.2%) | $100.18 M(+0.7%) |
| Mar 2018 | - | $24.70 M(-16.3%) | $99.51 M(+4.1%) |
| Dec 2017 | $95.59 M(+13.1%) | $29.52 M(+41.0%) | $95.59 M(+10.6%) |
| Sep 2017 | - | $20.94 M(-13.9%) | $86.44 M(+0.8%) |
| Jun 2017 | - | $24.34 M(+17.1%) | $85.78 M(+5.0%) |
| Mar 2017 | - | $20.79 M(+2.1%) | $81.70 M(-3.3%) |
| Dec 2016 | $84.51 M(-6.3%) | $20.37 M(+0.4%) | $84.51 M(-4.2%) |
| Sep 2016 | - | $20.29 M(+0.1%) | $88.21 M(-2.8%) |
| Jun 2016 | - | $20.26 M(-14.1%) | $90.77 M(-1.4%) |
| Mar 2016 | - | $23.60 M(-1.9%) | $92.05 M(+2.0%) |
| Dec 2015 | $90.20 M(+25.9%) | $24.06 M(+5.3%) | $90.20 M(+2.6%) |
| Sep 2015 | - | $22.84 M(+6.0%) | $87.91 M(+6.2%) |
| Jun 2015 | - | $21.55 M(-0.9%) | $82.77 M(+11.3%) |
| Mar 2015 | - | $21.75 M(-0.1%) | $74.34 M(+3.8%) |
| Dec 2014 | $71.65 M(+99.4%) | $21.77 M(+23.0%) | $71.65 M(+16.2%) |
| Sep 2014 | - | $17.70 M(+35.0%) | $61.66 M(+16.9%) |
| Jun 2014 | - | $13.12 M(-31.1%) | $52.76 M(+9.5%) |
| Mar 2014 | - | $19.05 M(+61.7%) | $48.20 M(+34.1%) |
| Dec 2013 | $35.93 M(+39.7%) | $11.79 M(+33.9%) | $35.93 M(+48.8%) |
| Sep 2013 | - | $8.80 M(+2.9%) | $24.15 M(+57.4%) |
| Jun 2013 | - | $8.56 M(+26.1%) | $15.35 M(+126.1%) |
| Mar 2013 | - | $6.79 M | $6.79 M |
| Dec 2012 | $25.73 M | - | - |
FAQ
- What is Theravance Biopharma annual SGA?
- What is the all time high annual SGA for Theravance Biopharma?
- What is Theravance Biopharma annual SGA year-on-year change?
- What is Theravance Biopharma quarterly SGA?
- What is the all time high quarterly SGA for Theravance Biopharma?
- What is Theravance Biopharma quarterly SGA year-on-year change?
- What is Theravance Biopharma TTM SGA?
- What is the all time high TTM SGA for Theravance Biopharma?
- What is Theravance Biopharma TTM SGA year-on-year change?
What is Theravance Biopharma annual SGA?
The current annual SGA of TBPH is $70.09 M
What is the all time high annual SGA for Theravance Biopharma?
Theravance Biopharma all-time high annual SGA is $108.53 M
What is Theravance Biopharma annual SGA year-on-year change?
Over the past year, TBPH annual SGA has changed by -$3.98 M (-5.37%)
What is Theravance Biopharma quarterly SGA?
The current quarterly SGA of TBPH is $16.88 M
What is the all time high quarterly SGA for Theravance Biopharma?
Theravance Biopharma all-time high quarterly SGA is $33.05 M
What is Theravance Biopharma quarterly SGA year-on-year change?
Over the past year, TBPH quarterly SGA has changed by +$733.00 K (+4.54%)
What is Theravance Biopharma TTM SGA?
The current TTM SGA of TBPH is -$3.72 B
What is the all time high TTM SGA for Theravance Biopharma?
Theravance Biopharma all-time high TTM SGA is -$17.04 M
What is Theravance Biopharma TTM SGA year-on-year change?
Over the past year, TBPH TTM SGA has changed by -$3.79 B (-5310.86%)